Interestingly, recent literature data, obtained in solid tumors including colorectal carcinoma, have suggested that both IL-15/IL-15α axis and TGF-β/SMAD-3 pathway are also involved in determining the effectiveness of the anti-EGFR agent, cetuximab. The gene discussed is TGFB1; the disease is colorectal carcinoma.